Drug Interactions between Pepcid AC and tepotinib
This report displays the potential drug interactions for the following 2 drugs:
- Pepcid AC (famotidine)
- tepotinib
Interactions between your drugs
No interactions were found between Pepcid AC and tepotinib. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Pepcid AC
A total of 313 drugs are known to interact with Pepcid AC.
- Pepcid ac is in the drug class H2 antagonists.
- Pepcid ac is used to treat the following conditions:
tepotinib
A total of 288 drugs are known to interact with tepotinib.
- Tepotinib is in the drug class multikinase inhibitors.
- Tepotinib is used to treat Non Small Cell Lung Cancer.
Drug and food interactions
tepotinib food
Applies to: tepotinib
ADJUST DOSING INTERVAL: Food enhances the oral bioavailability of tepotinib. When tepotinib was administered after a high-fat, high-calorie meal (approximately 800 to 1000 calories; 150 calories from protein, 250 calories from carbohydrate, 500 to 600 calories from fat), tepotinib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 2-fold and 1.6-fold, respectively, compared to administration under fasted conditions.
MANAGEMENT: Tepotinib should be administered with food at approximately the same time each day.
References (1)
- (2021) "Product Information. Tepmetko (tepotinib)." EMD Serono Inc
famotidine food
Applies to: Pepcid AC (famotidine)
H2 antagonists may reduce the clearance of nicotine. Cimetidine, 600 mg given twice a day for two days, reduced clearance of an intravenous nicotine dose by 30%. Ranitidine, 300 mg given twice a day for two days, reduced clearance by 10%. The clinical significance of this interaction is not known. Patients should be monitored for increased nicotine effects when using the patches or gum for smoking cessation and dosage adjustments should be made as appropriate.
References (1)
- Bendayan R, Sullivan JT, Shaw C, Frecker RC, Sellers EM (1990) "Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans." Eur J Clin Pharmacol, 38, p. 165-9
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.